Biomedical papers, 2016 (vol. 160), issue 4

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2016, 160(4):518-523 | 10.5507/bp.2016.025

The impact of Angiotensin II Type 1 Receptor antibodies on morbidity and mortality in Heart Mate II supported recipients

Marian Urbana, Antonij Slavcevb, Tomas Gazdicc, Peter Ivaka, Ivan Netukaa
a Department of Cardiac Surgery, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
b Department of Clinical Immunology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
c Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic

Aims: One of the proposed limitations of left ventricular assist device (LVAD) therapy is high degree of sensitization. Apart from human leukocyte antigen (HLA), antibodies against Angiotensin II Type 1 Receptor (AT1R) have been associated with adverse outcomes. The purpose of this study was to compare complications and survival of anti - AT1R positive versus negative Heart Mate II (HMII) recipients.

Methods: Altogether 96 patients received HMII at our institution between 2008 and 2012. These were stratified into three groups: antibody positive before implantation (AT1R+), antibody conversion during support (AT1R-/+) and patients who remained antibody negative (AT1R-). Survival, major on-device adverse events and post-transplant rejections were assessed with Kaplan-Meier and log-rank tests.

Results: Two year on-device and overall survival was 78 ± 12% and 75 ± 10% in AT1R-, 60 ± 23% and 60 ± 15% in AT1R+ and 92 ± 6% and 87 ± 5% in AT1R-/+ group (P = 0.409, P = 0.185). Freedom from major adverse event at two years for AT1R-, AT1R+ and AT1R-/+ was 49 ± 14%, 53 ± 16% and 41 ± 11% (P = 0.875). Freedom from rejection was 63 ± 17% in patients who were both anti-AT1R and HLA negative and 65 ± 13% in those who were antibody positive (P = 0.788).

Conclusion: Patients who were anti-AT1R antibody positive had similar on-device survival and rate of complications in comparison to those who were antibody negative. In transplanted patients, there were no differences in the overall survival and rejection between the groups.

Keywords: Heart Mate II, LVAD, Angiotensin II Type 1 Receptor, heart transplantation

Received: February 1, 2016; Accepted: April 19, 2016; Prepublished online: April 27, 2016; Published: December 12, 2016


References

  1. Trivedi JR, Cheng A, Singh R, Williams ML, Slaughter MS. Survival on the heart transplant waiting list: impact of continuous flow left ventricular assist device as bridge to transplant. Ann Thorac Surg 2014;98:830-4. Go to original source... Go to PubMed...
  2. Barten MJ, Dragun D, von Salisch S, Dieterlen MT, Garbade J, Klein S, Dhein S, Mohr FW, Bittner HB. Identification of Non-HLA Antibodies in Ventricular Assist Device Recipients. J Heart Lung Transplant 2012;31:S46. Go to original source...
  3. Dragun D, Muller DN, Brasen JH, Fritsche L, Nieminen-Kehla M, Dechend R, Kintscher U, Rudolph B, Hoebeke J, Eckert D, Mazak I, Plehm R, Schonemann C, Unger T, Budde K, Neumayer HH, Luft FC, Wallukat G. Angiotensin II type 1 receptor activating antibodies in renal-allograft rejection. N Engl J Med 2005;352:558-69. Go to original source... Go to PubMed...
  4. Reinsmoen NL, Lai CH, Mirocha J, Cao K, Ong GD, Naim M, Wang Q, Riega S, Rafiei M, Patel J, Kobashigawa J. Increased Negative Impact of Anti-Angiotensin Type 1 Receptor Antibodies Together with De Novo Donor HLA Specific Antibodies on Graft Outcome in Heart Transplant Recipients. J Heart Lung Transplant 2013;32:S113. Go to original source...
  5. Hiemann NE, Meyer R, Wellnhofer E, Schoenemann C, Heidecke H, Lachmann N, Hetzer R, Dragun D. Non-HLA antibodies targeting vascular receptors enhance alloimmune response and microvasculopathy after heart transplantation. Transplantation 2012;94:919-24. Go to original source... Go to PubMed...
  6. Kirklin JK, Naftel DC, Pagani FD, Kormos RL, Stevenson LW, Blume ED, Miller MA, Baldwin JJ, Young JB. Sixth INTERMACS annual report: A 10,000-patient database. J Heart Lung Transplant 2014;33:555-64. Go to original source... Go to PubMed...
  7. Drakos SG, Stringham JC, Long JW, Gilbert EM, Fuller TC, Campbell BK, Horne BD, Hagan ME, Nelson KE, Lindblom JM, Meldrum PA, Carlson JF, Moore SA, Kfoury AG, Renlund DG. Prevalence and risks of allosensitization in HeartMate left ventricular assist device recipients: the impact of leukofiltered blood product transfusions. J Thorac Cardiovasc Surg 2007;133:1612-19. Go to original source... Go to PubMed...
  8. McKenna DH, Eastlund T, Segall M, Noreen HJ, Park SJ. HLA alloimmunization in patients requiring ventricular assist device support. J Heart Lung Transplant 2002;21:1218-24. Go to original source... Go to PubMed...
  9. Massad MG, Cook DJ, Schmitt SK, Smedira NG, McCarthy JF, Vargo RL, McCarthy PM. Factors influencing HLA sensitization in implantable LVAD recipients. Ann Thorac Surg 1997;64:1120-25. Go to original source... Go to PubMed...
  10. Barten MJ, Dragun D, Dieterlen MT, Salisch Sv, Garbade J, Klein S, Dhein S, Mohr FW, Bittner HB. Non-HLA Antibody Screening after Heart Transplantation Identifies High Risk for Cardiac Allograft Vasculopathy. J Heart Lung Transplant 2012;31:S107. Go to original source...
  11. Dragun D. The role of angiotensin II type 1 receptor -activating antibodies in renal allograft vascular rejection. Pediatr Nephrol 2007;22:911. Go to original source... Go to PubMed...
  12. Dechend R, Homuth V, Wallukat G, Kreuzer J, Park JK, Theuer J, Juepner A, Gulba DC, Mackman N, Haller H, Luft FC. AT(1) receptor agonistic antibdies from preeclamptic patients cause vascular cells to express tissue factor. Circulation 2000;101:2382-7. Go to original source... Go to PubMed...
  13. Xia Y, Zhou CC, Ramin SM, Kellems RE. Angiotensin receptors, autoimmunity, and preeclampsia. J Immunol 2007;179:3391-5. Go to original source... Go to PubMed...
  14. Yang S, Zhong Q, Qiu Y, Chen X, Chen F, Mustafa K, Ding D, Zhou Y, Lin J, Yan S, Deng Y, Wang M, Zhou Y, Liao Y, Zhou Z. Angiotensin II receptor type 1 autoantibodies promote endothelial microparticles formation through activating p38 MAPK pathway. J Hypertens 2014;32:762-70. Go to original source... Go to PubMed...
  15. Zhang SL, Du YH, Wang J, Yang LH, Yang XL, Zheng RH, Wang YWK, Zhang MS, Liu HR. Endothelial dysfunction induced by antibodies against angiotensin AT1 receptor in immunized rats. Acta Pharmacol Sin 2010;31:1381-8. Go to original source... Go to PubMed...
  16. Du Q, Wu J, Wang H, Wang X, Xu L, Zhang Z, Liu J, Zhang J, Chen J, Hakonarson H, Hu A, Zhang L. Perindopril treatment promote left ventricle remodeling in patients with heart failure screened positive for autoantibodies against angiotensin II type 1 receptor. BMC Cardiovasc Disord 2013;13:94. Go to original source... Go to PubMed...
  17. Dragun D, Philippe A, Catar R. Role of non-HLA antibodies in organ transplantation. Curr Opin Organ Transplant 2012;17:440-5. Go to original source... Go to PubMed...
  18. Win TS, Pettigrew GJ. Humoral autoimmunity and transplant vasculopathy: when allo is not enaugh. Transplantation 2010;90:113. Go to original source... Go to PubMed...
  19. Mogi M, Iwai M, Horiuchi M. New insighs into the regulation of angiotensin receptors. Curr Opin Nephrol Hypertens 2009;18:138-43. Go to original source... Go to PubMed...
  20. van Geel PP, Pinto YM, Voors AA, Buikema H, Oosterga M, Crijns HJ, van Gilst WH. Angiotensin II type 1 receptor A1166C gene polymorhism is associated with an incresed response to angiotensin II in human arteries. Hypertension 2000;35:717-21. Go to original source... Go to PubMed...
  21. Wu J, You J, Wang S, Zhang L, Gong H, Zou Y. Insights into the activation and inhibition of Angiotensin II Type 1 Receptor in the mechanically loaded heart. Circ J 2014;78:1283-9. Go to original source... Go to PubMed...
  22. Storch U, Mederos Y, Schnitzler M, Gudermann T. G protein-mediated stretch reception. American Journal of Physiology. Am J Physiol Heart Circ Physiol 2012;302:H1241-9. Go to original source... Go to PubMed...
  23. Dragun D, Hegner B. Non-HLA antibodies post-transplantation: clinical relevance and treatment in solid organ transplantation. Contrib Nephrol 2009;162:129. Go to original source... Go to PubMed...
  24. Kaminska D, Tyran B, Mazanowska O, Rabczynski J, Szyber P, Patrzalek D, Chudoba P, Polak W, Klinger M. Cytokine gene expression in kidney allograft biopsies after donor brain death and ischemia-reperfusion injury using in situ reverse-transcription polymerase chain reaction analysis. Transplantation 2007;84:1118. Go to original source... Go to PubMed...